Connect your AI

Arvinas ARVN Accumulated Depreciation

Accumulated Depreciation at other companies

Nurix Therapeutics, Inc.NRIX

$39.72M+8.1%

Inhibrx Biosciences, Inc.INBX

$11.66M+21.8%

Nuvation BioNUVB

$1.18M+35.5%

Merck & Co.MRK

$22.29B+13.3%

Other financials

Income statement

Revenue$15.6M-91.7%

Operating income-$63.8M-189%

Net income-$57.6M-169%

EPS (diluted)-$0.90-179%

Balance sheet

Cash & equivalents$87.3M+7.8%

Total debt$8.6M-19.6%

Total equity$386.8M-41.4%

Total assets$647.5M-35.3%

Cash flow

Operating cash flow-$69.2M+22.2%

CapEx$1.3M+225%

Free cash flow-$70.5M+21.1%

Valuation

Market cap$518.11M-4.6%

Enterprise value$439.41M-7.1%

P/S5.8×+4.5×

Profitability

Operating margin-283.8%-310pp

Net margin-247.5%-260pp

FCF margin-287.4%—

Returns & leverage

Return on equity-42.3%-53.5pp

Debt / equity0×0.0×

Current ratio5.4×+0.9×

Where this comes from

Reported directly by Arvinas in its filing.

Tagged under the XBRL concept us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment.

The official record: Arvinas’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arvinas's accumulated depreciation.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Arvinas's accumulated depreciation?: Arvinas (ARVN) reported accumulated depreciation of $28.5M in Q1 2026.
How has Arvinas's accumulated depreciation changed year-over-year?: Arvinas's accumulated depreciation increased by 10.0% year-over-year, from $25.9M to $28.5M.
What is the long-term trend for Arvinas's accumulated depreciation?: Over 4 years (2021 to 2025), Arvinas's accumulated depreciation has grown at a 27.4% compound annual growth rate (CAGR), from $10.7M to $28.2M.
What does accumulated depreciation mean?: Total accumulated depreciation on property, plant, and equipment since acquisition — represents the consumed portion of asset useful lives.